Biogen Agrees To Pay $22 Million To Resolve Alleged False Claims Act Liability For Paying Kickbacks
Pharmaceutical company Biogen has agreed to pay $22 million to resolve claims that it illegally used foundations as conduits to pay the copays of Medicare patients taking Biogen’s multiple sclerosis drugs Avonex and Tysabri.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.